# CRESTONE (NCT04383210)

> Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04383210
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Elevation Oncology
- Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor; Pancreatic Cancer; Lung Cancer; Head and Neck Cancer; Breast Cancer; Kidney Cancer; Colorectal Cancer; Bladder Cancer; Ovarian Cancer; Sarcoma; Gallbladder Cancer; Bile Duct Cancer; Esophageal Cancer; Uterine Cancer; Cholangiocarcinoma; Prostate Cancer
- Interventions: Seribantumab
- Enrollment: 54
- Primary outcome: Objective Response Rate

## Indexed commentary on CRESTONE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- Podcasts: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=crestone-nct04383210

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04383210", "email": "<work email>"}; the inbox owner confirms by the emailed link.